Interacciones de Lapatinib

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

In animal reproductive studies, administration of lapatinib to pregnant rats during the period of organogenesis and through lactation led to death of offspring within the first 4 days after birth at maternal exposures that were ≥ 3.3 times the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

P-glycoprotein The concomitant use of colchicine capsules and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology (12) ] . (etiqueta de Colchicina, Interacciones medicamentosas)

Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6) ] . (etiqueta de Dabigatrán, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (etiqueta de Rimegepant, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

• Avoid concomitant use with strong CYP3A4/P-gp inducers or strong CYP3A4/P-gp inhibitors that decrease or increase sirolimus concentrations ( 7.4 , 12.3 ). (etiqueta de Sirolimus, Interacciones medicamentosas)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (etiqueta de Sofosbuvir y velpatasvir, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (etiqueta de Talazoparib, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Avoid concomitant use HYCAMTIN capsules with P-gp inhibitors or BCRP inhibitors. (etiqueta de Topotecán, Interacciones medicamentosas)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Avoid strong CYP3A4 inhibitors. (etiqueta de Lapatinib, Interacciones medicamentosas)

P-glycoprotein (P-gp) Inhibitors : Co-administration of P-gp inhibitors can increase afatinib exposure. (etiqueta de Afatinib, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

P-gp Inhibitors Treatment of NVAF Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose. (etiqueta de Edoxabán, Interacciones medicamentosas)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (etiqueta de Eltrombopag, Interacciones medicamentosas)

Coadministration of DESCOVY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. (etiqueta de Emtricitabina y tenofovir, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. (etiqueta de Fidaxomicina, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

…Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etiqueta de Lomitapida, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

Midazolam : Following coadministration of TYKERB and midazolam (CYP3A4 substrate), 24-hour systemic exposure (AUC) of orally administered midazolam increased 45%, while 24-hour AUC of intravenously administered midazolam increased 22%. (etiqueta de Lapatinib, Interacciones medicamentosas)

P-Glycoprotein (P-gp) Inhibitors Clinical Impact: The concomitant use of P-gp inhibitors can increase the exposure to morphine by two-fold and can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. (etiqueta de Morfina, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

Paclitaxel : In cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. (etiqueta de Lapatinib, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (etiqueta de Lapatinib, Interacciones medicamentosas)

• Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (etiqueta de Rifaximina, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

TYKERB may prolong the QT interval in some patients. (etiqueta de Lapatinib, Advertencias y precauciones)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (etiqueta de Lapatinib, Interacciones medicamentosas)

Lenacapavir (LEN), a component of BIXLENVO, is a moderate inhibitor of CYP3A and a P-gp inhibitor. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. (etiqueta de Dapagliflozina, Interacciones medicamentosas)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (etiqueta de Eribulina, Interacciones medicamentosas)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (etiqueta de Lapatinib, Interacciones medicamentosas)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (etiqueta de Lapatinib, Interacciones medicamentosas)

Substrates and Inhibitors of P-glycoprotein It has been shown in vitro that mefloquine is a substrate and an inhibitor of P-glycoprotein. (etiqueta de Mefloquina, Interacciones medicamentosas)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (etiqueta de Lapatinib, Interacciones medicamentosas)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (etiqueta de Lapatinib, Interacciones medicamentosas)

Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P‑gp substrate. (etiqueta de Silodosina, Interacciones medicamentosas)

Mechanism and Clinical Effect(s) Vepdegestrant is a P-gp inhibitor. (etiqueta de Vepdegestrant, Interacciones medicamentosas)